Beyond Hormone Receptor Positivity: Prognostic Value of ER, PR, and Ki-67 Expression Levels in CDK4/6 Inhibitor-Treated Metastatic Breast Cancer: A Multicenter Real-World Study
Background and Objectives: Clinical outcomes remain heterogeneous in patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer receiving cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. We evaluated the prognostic relevance and incremental prognostic value of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 expression beyond clinical and treatment-related factors. Materials and Methods: This multicenter retrospective study included 568 patients treated with ribociclib- or palbociclib-based therapy between 2019 and 2024. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan–Meier and Cox regression analyses. The incremental prognostic value of ER, PR, and Ki-67 was assessed using nested Cox models with identical baseline clinical covariates and patient samples. Additional spline and exploratory cut-off analyses were performed. Results: Median PFS and OS were 29.23 and 44.43 months, respectively. Liver metastasis was independently associated with shorter PFS (HR 1.77, 95% CI 1.27–2.48; p = 0.001) and OS (HR 1.80, 95% CI 1.24–2.61; p = 0.002). Lung metastasis and prior endocrine therapy were independently associated with shorter PFS, whereas older age and prior endocrine therapy were associated with shorter OS. Although higher PR and lower Ki-67 expression were associated with longer PFS in univariable analyses, higher Ki-67 expression was independently associated with shorter PFS in the multivariable model (HR 1.008, p = 0.025), whereas ER and PR were not significantly associated with PFS or OS. Adding ER, PR, and Ki-67 to baseline clinical models did not significantly improve model fit for PFS (p = 0.087) or OS (p = 0.320). No significant nonlinear associations were identified, and exploratory cut-offs demonstrated limited stability. Exploratory subgroup analyses suggested incremental prognostic value in first-line treatment (p = 0.003), although the treatment-line interaction was not significant. Conclusions: Ki-67 showed an independent association with PFS, although the combined incremental prognostic value of ER, PR, and Ki-67 beyond clinical factors was limited. Further prospective studies are warranted to clarify their clinical utility.
Authors
- Ece Ulukal Karancı (ORCID: https://orcid.org/0000-0002-0930-1016)
- Derya Kıvrak Salim (ORCID: https://orcid.org/0000-0003-4107-3460)
- Esma Uguztemur (ORCID: https://orcid.org/0000-0003-1822-3870)
- Ahmet Fatih Oruç (ORCID: https://orcid.org/0009-0003-0923-5148)
- Atila Yıldırım (ORCID: https://orcid.org/0000-0002-6067-5646)
- Seval Akay (ORCID: https://orcid.org/0000-0002-1235-6739)
- Seval Ay (ORCID: https://orcid.org/0000-0002-7555-2657)
- Ahmet Kürşad Dişli (ORCID: https://orcid.org/0000-0001-8014-4140)
- Şafak Yıldırım Dişli (ORCID: https://orcid.org/0000-0002-5869-0679)
- Banu Öztürk (ORCID: https://orcid.org/0000-0003-0290-8787)
- Esra Aşık (ORCID: https://orcid.org/0000-0003-3030-2475)
- Melek Eryilmaz Karakurt
Institutions
- Karadeniz Technical University (TR)
- Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi (TR)
- Necmettin Erbakan University (TR)
- Antalya Eğitim ve Araştırma Hastanesi (TR)
- İzmir Şehir Hastanesi (TR)
- Antalya Şehi̇r Hastanesi̇ (TR)
- Kirsehir Training and Research Hospital (TR)
- Adıyaman Eğitim ve Araştırma Hastanesi (TR)
Publication Details
- Journal
- Medicina
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3390/medicina62112275
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00